Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study

• Status: Completed
• Trial end date: 2017-07-13

Summary

The primary objective is to describe the effectiveness of dasatinib (Sprycel®) in CML patients in China in the real-world clinical practice setting.

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Dasatinib